Strategies to Overcome Multi-Drug Resistance in Cancer Cells: the Contribution of siRNA and Nanotechnologies

Author(s): Cristina Mambet, Mihaela Chivu-Economescu, Lilia Matei, Mihai Stoian, Coralia Bleotu

Journal Name: Current Organic Chemistry

Volume 20 , Issue 28 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Current therapeutic strategies used in many types of cancer are confronted with the major problem of multidrug resistance (MDR) that can be acquired through several mechanisms. To overcome this limitation, new therapeutic options are being explored involving state-of-the-art technologies. In this respect, small- interfering RNA (siRNA) technology offers the possibility to block the expression of genes that are involved in the MDR development, improving the therapeutic index of anticancer drugs. Nanocarriers are promising delivery systems for small molecule drugs as well as for nucleic acids aiming to target specifically the cancer cells and to counteract MDR. Several types of organic and inorganic nanocarriers will be discussed in this review, together with their advantages and limitations in delivery of targeted siRNAs and cytotoxic drugs, using in vivo and in vitro experiments. Although siRNA-anticancer drug co-delivery employing nanocarriers seems to be associated with a higher antitumor activity than single drug or nucleic acid administration, more studies are needed to evaluate the efficacy and the toxicity of various nanoparticle delivery systems.

Keywords: Multidrug resistance (MDR), nanocarriers, siRNA, drug delivery systems, co-delivery, liposomes, micelleplexes, inorganic nanoparticles.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 10 May, 2016
Page: [2971 - 2982]
Pages: 12
DOI: 10.2174/1385272820666160510163625
Price: $65

Article Metrics

PDF: 58
PRC: 1